PP
CBIO

PDT Partners’s Crescent Biopharma CBIO Stock Holding History

PDT Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-823
Closed -$191K – 820
2021
Q2 		$191K Hold
823
– – 0.01% 708
2021
Q1 		$248K Buy
823
+307
+59% +$110K 0.02% 658
2020
Q4 		$194K Buy
+516
New +$181K 0.01% 613
2020
Q3 		– Sell
-419
Closed -$158K – 774
2020
Q2 		$158K Hold
419
– – 0.01% 607
2020
Q1 		$96K Sell
419
-2
-0.5% -$764 0.01% 615
2019
Q4 		$222K Buy
+421
New +$228K 0.01% 622

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PDT Partners's CBIO Position: Q3 2021 in Review

PDT Partners sold out of Crescent Biopharma (CBIO) in Q3 2021, closing a stake of 823 shares — an estimated $191K sold.

PDT Partners first reported a position in CBIO in Q4 2019 and held it in 6 quarters. The position peaked at $248K in Q1 2021. 47 funds tracked by Wall St. Rank hold CBIO as of Q3 2021.

  • PDT Partners reported no remaining Crescent Biopharma position as of Q3 2021 after selling out during the quarter.
  • PDT Partners sold 823 Crescent Biopharma shares in Q3 2021, an estimated $191K.
  • PDT Partners first reported a position in Crescent Biopharma in Q4 2019 and held it in 6 quarters.
  • PDT Partners's Crescent Biopharma position peaked at $248K in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.